Literature DB >> 16495541

CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice.

Yao-Shen Chen1, Yu-Shan Hsiao, Hsi-Hsun Lin, Yin Liu, Ya-Lei Chen.   

Abstract

The plasmid DNA encoding the fliC gene of Burkholderia pseudomallei combined with CpG oligodeoxynucleotide (ODN) was injected intramuscularly into BALB/c mice, resulting in the increased production of certain humoral antibodies and flagellin-specific spleen cell clonal expansion. CpG ODN, as an immunoadjuvant, was added to the plasmid containing the fliC gene in order to obtain ongoing expression in muscle for a long period. Functional expression of flagellin from the constructed CpG-modified plasmid in transfected peritoneal exudate cells of BALB/c mice was shown by reverse transcription-PCR and Western blotting. Furthermore, BALB/c mice immunized with the modified plasmid had relatively higher resistance to B. pseudomallei infection in vivo than did mice immunized with unmodified plasmid DNA. The time course of restricted bacterial growth in spleen and liver and changes in the cytokine profiles of immunized mice suggested that the stimulated phagocytic cells would be able to kill the bacteria eventually, possibly as a consequence of the induction of Th-1-type immune polarization in vivo. Th-1-type immune polarization was detected in response to flagellin induction in mice immunized with CpG-modified plasmid DNA by the appearance of increased levels of immunoglobulin G2a antibodies and gamma interferon-secreting cells specific to flagellin. The exogenous CpG motifs added to the fliC gene would contribute to an adjuvant-like response that enhances the flagellin-specific immunogenicity and provides protection against B. pseudomallei infection. This CpG-modified plasmid DNA vaccination is an important potential strategy that should be developed to protect against melioidosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495541      PMCID: PMC1418635          DOI: 10.1128/IAI.74.3.1699-1705.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins.

Authors:  S M Jones; J F Ellis; P Russell; K F Griffin; P C F Oyston
Journal:  J Med Microbiol       Date:  2002-12       Impact factor: 2.472

Review 4.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

5.  Burkholderia pseudomallei virulence: definition, stability and association with clonality.

Authors:  G C Ulett; B J Currie; T W Clair; M Mayo; N Ketheesan; J Labrooy; D Gal; R Norton; C A Smith; J Barnes; J Warner; R G Hirst
Journal:  Microbes Infect       Date:  2001-07       Impact factor: 2.700

6.  Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin.

Authors:  Yao-Shen Chen; Yu-Shan Hsiao; His-Hsun Lin; Chuan-Min Yen; Ssu-Ching Chen; Ya-Lei Chen
Journal:  Vaccine       Date:  2005-09-06       Impact factor: 3.641

7.  Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis.

Authors:  F N Lauw; A J Simpson; J M Prins; M D Smith; M Kurimoto; S J van Deventer; P Speelman; W Chaowagul; N J White; T van der Poll
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

8.  Melioidosis: acute and chronic disease, relapse and re-activation.

Authors:  B J Currie; D A Fisher; N M Anstey; S P Jacups
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 May-Jun       Impact factor: 2.184

Review 9.  Pathogenesis of and immunity to melioidosis.

Authors:  P J Brett; D E Woods
Journal:  Acta Trop       Date:  2000-02-05       Impact factor: 3.112

10.  Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei.

Authors:  G C Ulett; N Ketheesan; R G Hirst
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

View more
  25 in total

1.  CD4+ T cell epitopes of FliC conserved between strains of Burkholderia: implications for vaccines against melioidosis and cepacia complex in cystic fibrosis.

Authors:  Julie A Musson; Catherine J Reynolds; Darawan Rinchai; Arnone Nithichanon; Prasong Khaenam; Emmanuel Favry; Natasha Spink; Karen K Y Chu; Anthony De Soyza; Gregory J Bancroft; Ganjana Lertmemongkolchai; Bernard Maillere; Rosemary J Boyton; Daniel M Altmann; John H Robinson
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

2.  CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis.

Authors:  Karen K Chu; Patcharaporn Tippayawat; Nicola J Walker; Sarah V Harding; Helen S Atkins; Bernard Maillere; Gregory J Bancroft; Ganjana Lertmemongkolchai; Daniel M Altmann
Journal:  Eur J Immunol       Date:  2010-12-03       Impact factor: 5.532

3.  Burkholderia pseudomallei proteins presented by monocyte-derived dendritic cells stimulate human memory T cells in vitro.

Authors:  Patcharaporn Tippayawat; Maneerat Pinsiri; Darawan Rinchai; Donporn Riyapa; Amornrat Romphruk; Yunn-Hwen Gan; Raymond L Houghton; Philip L Felgner; Richard W Titball; Mark P Stevens; Edouard E Galyov; Gregory J Bancroft; Ganjana Lertmemongkolchai
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

4.  Role of Toll-Like Receptor 5 (TLR5) in Experimental Melioidosis.

Authors:  Emma Birnie; Tassili A F Weehuizen; Jacqueline M Lankelma; Hanna K de Jong; Gavin C K W Koh; Miriam H P van Lieshout; Joris J T H Roelofs; Andries E Budding; Alex F de Vos; Tom van der Poll; W Joost Wiersinga
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

5.  Sequence polymorphism and PCR-restriction fragment length polymorphism analysis of the flagellin gene of Burkholderia pseudomallei.

Authors:  Sun Tee Tay; Pui Ching Cheah; Savithiri D Puthucheary
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

6.  Distribution of melioidosis cases and viable Burkholderia pseudomallei in soil: evidence for emerging melioidosis in Taiwan.

Authors:  Yao-Shen Chen; Hsi-Hsun Lin; Jung-Jung Mu; Chuen-Sheue Chiang; Chang-Hsun Chen; Leh-Mia Buu; Yusen E Lin; Ya-Lei Chen
Journal:  J Clin Microbiol       Date:  2010-02-10       Impact factor: 5.948

7.  DNA vaccination resurfaces in the struggle against melioidosis.

Authors:  Sophie A Aschenbroich
Journal:  Virulence       Date:  2017-06-02       Impact factor: 5.882

8.  Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.

Authors:  Arnone Nithichanon; Louise J Gourlay; Gregory J Bancroft; Manabu Ato; Yoshimasa Takahashi; Ganjana Lertmemongkolchai
Journal:  Immunology       Date:  2017-02-09       Impact factor: 7.397

9.  Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.

Authors:  Yun-Zhou Yu; Yao Ma; Wen-Hui Xu; Shuang Wang; Zhi-Wei Sun
Journal:  Med Microbiol Immunol       Date:  2014-09-30       Impact factor: 3.402

10.  Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.

Authors:  David N Harland; Karen Chu; Ashraful Haque; Michelle Nelson; Nicola J Walker; Mitali Sarkar-Tyson; Timothy P Atkins; Benjamin Moore; Katherine A Brown; Gregory Bancroft; Richard W Titball; Helen S Atkins
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.